New Enterprise Associates 16, L.P. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 6:57 pm Unchanged | 2024-11-06 | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16, L.P. | 15,074,080 18.700% | 0 (Unchanged) | Filing |
| 2024-05-21 6:34 pm Purchase | 2024-05-07 | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16, L.P. | 15,074,080 20.300% | 703,704 (+4.90%) | Filing |
| 2022-04-25 5:04 pm Purchase | 2022-04-11 | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16, L.P. | 14,370,376 42.500% | 6,580,526 (+84.48%) | Filing |
| 2021-11-02 09:09 am Purchase | 2021-10-18 | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16, L.P. | 7,789,850 36.100% | 1,851,852 (+31.19%) | Filing |
| 2020-04-16 4:26 pm Purchase | 2020-04-03 | 13D | Trevi Therapeutics, Inc. TRVI | New Enterprise Associates 16, L.P. | 5,937,998 33.300% | 1,499,436 (+33.78%) | Filing |